Ligand Pharmaceuticals (LGND) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 6, 2025, to be held virtually at 11:30 am Eastern Time.

• Proxy materials and annual report for the year ended December 31, 2024, are available online for review and voting.

• Shareholders are encouraged to access materials electronically and can request paper copies if needed.

Voting matters and shareholder proposals

• Election of eight directors is up for shareholder vote, with the board recommending a vote FOR all nominees.

• Ratification of Ernst & Young LLP as the independent registered accounting firm for fiscal year ending December 31, 2025.

• Advisory approval of executive compensation for named executive officers is proposed.

Board of directors and corporate governance

• Board nominees include Jason M. Aryeh, Todd C. Davis, Nancy R. Gray, Ph.D., Jason Haas, John W. Kozarich, Ph.D., John L. LaMattina, Ph.D., Stephen L. Sabba, M.D., and Martine Zimmermann, Pharm.D.